Travere Therapeutics appoints Ruth Williams-Brinkley to Board of Directors

Travere Therapeutics, Inc.

Board expanded from 10 to 11; Ms. Williams-Brinkley elected effective Sept 14, 2021.
Received initial grant: option for 15,750 shares and RSU for 5,250 shares, vesting over 3 years.
Annual retainer of $50,000; subsequent annual grants of option for 9,000 shares and RSU for 3,000 shares.
She is President of Kaiser Foundation Health Plan (Mid-Atlantic); Travere had ~$4.9M gross revenue from Kaiser (Jan 2020–Jun 2021).
Board determined Ms. Williams-Brinkley qualifies as independent under Nasdaq rules.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Ruth Williams-Brinkley

Director

TVTX · Travere Therapeutics, Inc.

Effective: 2021-09-14
Filed: September 14, 2021, 7:59 PM ET

On September 14, 2021, the Board of Directors (the “Board”) of Travere Therapeutics, Inc. (the “Company”) approved an increase in the size of the Board of Directors from 10 to 11 members and elected Ruth Williams-Brinkley to serve as a director of the Company, effective September 14, 2021.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Ruth Williams-Brinkley was elected as Director at Travere Therapeutics, Inc..

Action: elected
Role: Director

Exact text from the filing

On September 14, 2021, the Board of Directors (the “Board”) of Travere Therapeutics, Inc. (the “Company”) approved an increase in the size of the Board of Directors from 10 to 11 members and elected Ruth Williams-Brinkley to serve as a director of the Company, effective September 14, 2021.

View on SEC.gov

Travere Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001438533-21-000041

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.